UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q/A
AMENDMENT NO. 1
(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
For the quarterly period ended September 30, 1996
------------------
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transaction period from ______________ to _______________
Commission file number: 0-26642
-------
MYRIAD GENETICS, INC.
(Exact name of registrant as specified in its charter)
Delaware 87-0494517
-------- ----------
(State or other jurisdiction (I.R.S. Employer Identification No.)
of incorporation or organization
320 Wakara Way, Salt Lake City, UT 84108
---------------------------------- -----
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (801) 584-3600
390 Wakara Way, Salt Lake City, Utah
------------------------------------
(Former address, if changed since last report)
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
Yes [X] No [ ]
As of November 5, 1996, the registrant had 8,730,725 shares of common stock
outstanding.
The Purpose of this Form 10-Q/A Amendment No. 1 is to amend the previously
filed Form 10-Q of Myriad Genetics, Inc. for the quarterly period ended
September 30, 1996 by augmenting Item 6(a) of Part II thereto to include revised
Exhibits 10.1 and 10.4 which are herewith resubmitted and redacted pursuant to
that certain Confidentiality Request of Myriad Genetics, Inc. filed with the
Securities and Exchange Commission on November 12, 1996, as amended by letter
dated December 23, 1996. Such item is set forth in this Form 10-Q/A Amendment
No. 1
2
Item 6. Exhibits and Reports on Form 8-K.
(a) Exhibits
--------
The following is a list of exhibits filed as part of this Quarterly
Report on Form 10-Q.
Exhibit
Number Description
- ------- -----------
10.1 Patent and Technology License Agreement dated September 26, 1996 among the Board of Regents of The
University of Texas System, The University of Texas M.D. Anderson Cancer Center and the Company. The
Company has excluded from this Exhibit 10.1 portions of the Patent and Technology License Agreement for
which the Company has requested confidential treatment from the Securities and Exchange Commission. The
portions of the Patent and Technology License Agreement for which confidential treatment has been
requested are marked "[ ]" and such confidential portions have been filed separately with the
Securities and Exchange Commission.
10.2 Lease Agreement, dated October 12, 1995, between The Boyer Research Park Associates V, by its general
partner, The Boyer Company and the Company.
10.3 Amendment to Lease Agreement, dated March 29, 1996, between The Boyer Research Park Associates V, by
its general partner, The Boyer Company and the Company.
10.4 Letter Agreement, dated March 4, 1996, among The University of Utah, Genetic Epidemiology and the
Company regarding Extension of Standard Research Agreement and Form of License Agreement between the
Company and The University of Utah, effective January 1, 1993, as amended (Genes Predisposing to
Cancer). The Company has omitted from this Exhibit 10.4 portions of the Letter Agreement for which the
Company has requested confidential treatment from the Securities and Exchange Commission. The portions
of the Letter Agreement for which confidential treatment has been requested are marked "[ ]" and such
confidential portions have been filed separately with the Securities and Exchange Commission.
11.1 Statement Regarding Computation of Net Loss Per Share
27.1 Financial Data Schedule
(b) Reports on Form 8-K
-------------------
No reports on Form 8-K were filed during the quarter ended September 30, 1996.
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
MYRIAD GENETICS, INC.
Date: April 17, 1997 /s/ Jay M. Moyes
-------------- -----------------
Jay M. Moyes
Vice President of Finance
(principal financial and accounting officer)
4
MYRIAD GENETICS, INC.
EXHIBIT INDEX
Exhibit
Number Description
- ------- -----------
10.1 Patent and Technology License Agreement dated September 26, 1996 among the Board of Regents of The
University of Texas System, The University of Texas M.D. Anderson Cancer Center and the Company. The
Company has excluded from this Exhibit 10.1 portions of the Patent and Technology License Agreement for
which the Company has requested confidential treatment from the Securities and Exchange Commission. The
portions of the Patent and Technology License Agreement for which confidential treatment has been
requested are marked "[ ]" and such confidential portions have been filed separately with the
Securities and Exchange Commission.
10.2 Lease Agreement, dated October 12, 1995, between The Boyer Research Park Associates V, by its general
partner, The Boyer Company and the Company.
10.3 Amendment to Lease Agreement, dated March 29, 1996, between The Boyer Research Park Associates V, by
its general partner, The Boyer Company and the Company.
10.4 Letter Agreement, dated March 4, 1996, among The University of Utah, Genetic Epidemiology and the
Company regarding Extension of Standard Research Agreement and Form of License Agreement between the
Company and The University of Utah, effective January 1, 1993, as amended (Genes Predisposing to
Cancer). The Company has omitted from this Exhibit 10.4 portions of the Letter Agreement for which the
Company has requested confidential treatment from the Securities and Exchange Commission. The portions
of the Letter Agreement for which confidential treatment has been requested are marked "[ ]" and such
confidential portions have been filed separately with the Securities and Exchange Commission.
11.1 Statement Regarding Computation of Net Loss Per Share
27.1 Financial Data Schedule